<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368643">
  <stage>Registered</stage>
  <submitdate>27/05/2015</submitdate>
  <approvaldate>9/06/2015</approvaldate>
  <actrnumber>ACTRN12615000601538</actrnumber>
  <trial_identification>
    <studytitle>A Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral AD-6626 in Normal, Healthy Volunteers </studytitle>
    <scientifictitle>A Single-Center, Randomized, Double-Blind, Placebo Controlled, Multiple-Dose, Dose Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of AD 6626 Administered Orally to Normal, Healthy Volunteers </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>This study is for healthy volunteers. The intended use of the investigational product is the treatment of Fanconi Anemia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The study consists of sequential dose escalation with approximately 3 cohorts of subjects (8 subjects per cohort) given oral doses of AD-6626 or placebo given twice daily for 10 days. The doses of AD-6626 are 150mg, 300mg, and 600mg.  The AD-6626 is dissolved in cranberry juice for administration</interventions>
    <comparator>Placebo which is cranberry juice delivered as an oral solution</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Frequencies and types of AEs and SAEs through physical examination including vital signs, ECGs, pulse oximetry and safety laboratory tests</outcome>
      <timepoint>From the time of signed consent through the end of study date which occurs on Day 16</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of AD-6626 and its active metabolite as assessed through blood collection during the study</outcome>
      <timepoint>PK samples at the following timepoints
Day 0: within 5 minutes before Dose #1 and post Dose #1 at 15, 30, 45, 60, and 90 minutes and at 2, 3, 4, 6, 8, and 12 hours (before Dose #2).
- Days 1, 2, 3, 4, 5, and 7 (trough): within 5 minutes before the first dose each day.
- Day 9: within 5 minutes before Dose #19 and post Dose #19 at 15, 30, 45, 60, and 90 minutes and at 2,
3, 4, 6, 8, and 12 hours (before Dose #20).
- Day 10: at 12 and 24 hours post Dose #20.
- Day 11: at 36 and 48 hours post Dose #20.
- Day 12: at 72 hours post Dose #20.
- Day 16.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>This study will be conducted in normal, healthy, adult, male or female aged between 21-45 years and with a BMI greater than or equal to 18 and less than or equal to 30. Eligible subjects will be in good health without signs or symptoms of current illness and with predose clinical and laboratory examinations without clinically significant findings. </inclusivecriteria>
    <inclusiveminage>21</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>- History of clinically significant endocrine, neurological, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
- History of severe allergic or anaphylactic reactions 
- Fever (body temperature &gt;38 degrees celsius) or symptomatic viral or bacterial infection within 2 weeks prior to Screening
- Blood pressure (BP) &gt;140/90 mm Hg or a heart rate (HR) &gt;100 beats per minute at Screening and at Day -1 
- Clinically significant laboratory abnormalities 
- Female who is breastfeeding or has a positive pregnancy test at any visit</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>23/06/2015</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Aldea Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress>3696 Haven Avenue, Suite C Redwood City, CA 94063</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Aldea Pharmaceuticals</fundingname>
      <fundingaddress>3696 Haven Avenue, Suite C Redwood City, CA 94063</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study on healthy volunteers is to determine the safety and tolerability of multiple doses of oral AD-6626 in normal healthy volunteers </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Research &amp; Ethics Committee</ethicname>
      <ethicaddress>The Alfred Hospital
55 Commercial Road
Melbourne, Victoria 3004</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>28/04/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Jason Lickliter, MBBS PhD FRACP</name>
      <address>Nucleus Network Limited Level 5 Burnet Institute AMREP Precinct 89 Commercial Road Melbourne Victoria 3004</address>
      <phone>+61 3 9076 8960</phone>
      <fax />
      <email>j.lickliter@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jason Lickliter, MBBS PhD FRACP</name>
      <address>Nucleus Network Limited Level 5 Burnet Institute AMREP Precinct 89 Commercial Road Melbourne Victoria 3004</address>
      <phone>+61 3 9076 8960</phone>
      <fax />
      <email>j.lickliter@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Richard Shames</name>
      <address>ALDEA Pharmaceuticals 3696 Haven Avenue, Suite C Redwood City, CA 94063</address>
      <phone>+1 650-575-0798</phone>
      <fax />
      <email>rshames@aldeapharma.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>